Micro-cap and penny biotech stocks (those with a market cap at less than $300 million) have a reputation for being extremely speculative, volatile, and unpredictable.
But they can also deliver returns beyond your wildest expectations.
In fact, some of these companies have become legendary for minting millionaires, as they rocketed from bargain basement to stellar valuation. Others, of course, crashed and burned along the way.
In this investment niche, little is certain, but a little legwork can give you an edge when picking the winners from the also-rans.
In a moment, I'm going to show you two things I always look for when I'm researching these special stocks for my Biotech Insider Alert subscribers.
But first, I'll tell you what not to look for. That's going to save you a lot of time...
About the Author
Ernie Tremblay has more than 25 years of experience in following and analyzing the latest developments in health, medicine, and related technologies. He understands the FDA approval process, as well as the "hard science" behind new, experimental drugs and the market demand for them - and has a comprehensive grasp of the complex dynamics that determine whether a new drug will be a breakthrough winner, or just another casualty of the FDA approval process.